About

Company Overview

MOLTHERA is a privately held, U.S.-based biotechnology company advancing next-generation implantable therapeutic platforms for oncology applications. The company is currently operating at the preclinical development stage and is focused on localized therapeutic strategies addressing significant unmet needs in oncology.

MOLTHERA’s development approach emphasizes modular platform technologies, deliberate intellectual property strategy, and milestone-driven execution.

Development Focus

MOLTHERA is developing proprietary implantable technology platforms intended to enable localized therapeutic intervention in solid tumors. These platforms are designed to support multiple therapeutic strategies while prioritizing precision, durability, and translational feasibility.

The company’s work spans the intersection of biomaterials, localized delivery systems, and oncology, with an emphasis on scalable development pathways.

Leadership

Joshua S. Schoonover, Esq.
Founder & CEO

Mr. Schoonover is a biotechnology executive with experience spanning drug and device development strategy, intellectual property, regulatory planning, and corporate structuring. His work has focused on the creation and advancement of early-stage therapeutic and platform technologies, with particular emphasis on disciplined development planning and value inflection-driven execution.

Operating Philosophy

MOLTHERA operates with an IP-first, milestone-driven development philosophy. Intellectual property protection precedes public disclosure, and technical progress is gated through defined development and regulatory milestones.

The company collaborates selectively with specialized academic groups and contract research organizations to advance its programs efficiently and rigorously.

Company Snapshot

  • Privately held U.S. biotechnology company

  • Development-stage programs

  • Focused on oncology and implantable therapeutic platforms

  • Operating in stealth mode

Additional technical details may be shared with qualified partners under appropriate confidentiality arrangements.